Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

28.07
+0.28001.01%
Post-market: 28.080.0100+0.04%19:59 EDT
Volume:37.11M
Turnover:1.04B
Market Cap:159.60B
PE:36.94
High:28.43
Open:27.77
Low:27.66
Close:27.79
52wk High:28.75
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:1.05
T/O Rate:0.66%
Dividend:1.72
Dividend Rate:6.13%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.87
PE(LYR):20.57

Loading ...

Dow Jones Top Company Headlines at 5 PM ET: Nike Names Pfizer's Denton as Next CFO | FedEx ...

Dow Jones
·
Jun 24

Pfizer Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Jun 24

Option traders moderately bearish in Pfizer with shares down 0.74%

TIPRANKS
·
Jun 24

China outpacing Europe in drug innovation and development, Pfizer executive says

Reuters
·
Jun 24

Press Release: Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Dow Jones
·
Jun 23

Cantor Fitzgerald Keeps Their Hold Rating on Pfizer (PFE)

TIPRANKS
·
Jun 23

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pfizer (PFE) and Insulet (PODD)

TIPRANKS
·
Jun 23

BUZZ-Street View: Pfizer lung cancer drug miss a setback, but hopes persist in earlier treatment

Reuters
·
Jun 23

Jefferies Adjusts Price Target on Pfizer to $34 From $35, Maintains Buy Rating

MT Newswires Live
·
Jun 23

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Pfizer (PFE)

TIPRANKS
·
Jun 23

J.P. Morgan Remains a Hold on Pfizer (PFE)

TIPRANKS
·
Jun 23

Pfizer (PFE) Gets a Buy from Jefferies

TIPRANKS
·
Jun 23

Pfizer's Phase 3 Study of Sigvotatug Vedotin Misses Overall Survival Endpoint

MT Newswires Live
·
Jun 23

Pfizer's Lung Cancer Drug Trial Misses Endpoint

Dow Jones
·
Jun 23

Pfizer Inc Shares Fall 1% After the Bell Following Results After Phase 3 Study for Sigvotatug Vedotin Shows Does Not Improve Overall Survival

THOMSON REUTERS
·
Jun 23

Pfizer's experimental drug misses main goal of lung cancer trial

Reuters
·
Jun 23

Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint

TIPRANKS
·
Jun 23

Pfizer says Phase 3 SigVie-002 trial misses overall survival endpoint for sigvotatug vedotin in metastatic NSCLC

Reuters
·
Jun 23

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Jun 23

Pfizer - Sigvotatug Vedotin Shows Manageable Safety Profile Consistent With Prior Studies

THOMSON REUTERS
·
Jun 23